Share ownership Arrowhead Pharmaceuticals, Inc.

ARWR

US04280A1007

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 12/05/2026 BST			5-day change	1st Jan Change
79.04 ^USD	+1.67%		+5.49%	+19.05%

05-08	RBC Capital Adjusts Arrowhead Pharmaceuticals Price Target to $87 From $80, Maintains Outperform Speculative Risk Rating	MT
05-08	Arrowhead Pharmaceuticals, Inc., Q2 2026 Earnings Call, May 07, 2026

Share class: Arrowhead Pharmaceuticals, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	143,518,021	135,562,624 ( 94.46 %)	2,661,000 ( 1.854 %)	94.46 %

Major shareholders: Arrowhead Pharmaceuticals, Inc.

Name	Equities	%	Valuation
BlackRock Advisors LLC 14.49 %	20,293,888	14.49 %	1 491 M $
Avoro Capital Advisor LLC 7.588 %	10,625,000	7.588 %	781 M $
Vanguard Portfolio Management LLC 5.192 %	7,269,957	5.192 %	534 M $
Vanguard Portfolio Management LLC 5.103 %	7,146,136	5.103 %	525 M $
Vanguard Capital Management LLC 5.057 %	7,081,293	5.057 %	520 M $
Fidelity Management & Research Co. LLC 4.656 %	6,520,408	4.656 %	479 M $
STATE STREET CORPORATION 4.573 %	6,403,830	4.573 %	471 M $
Vanguard Capital Management LLC 4.308 %	6,032,416	4.308 %	443 M $
Christopher Anzalone 2.708 %	3,792,739	2.708 %	279 M $
Geode Capital Management LLC 2.332 %	3,264,963	2.332 %	240 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	84.27%
Other	6.32%
State Street Corp.	4.57%
Individuals	3.8%
Schweizerische Nationalbank	0.17%
SEI Investments Co.	0.12%
Silvercrest Asset Management Group, Inc.	0.11%
Manulife Financial Corp.	0.07%
Governments	0.07%
Fifth Third Bancorp	0.02%
The Allstate Corp.	0.01%
Unknown	0.47%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	85.64%
United Kingdom	3.99%
Individuals	3.8%
Norway	1.26%
Switzerland	1.19%
Canada	1.18%
Sweden	0.55%
Australia	0.48%
Netherlands	0.26%
Denmark	0.24%
Singapore	0.23%
Germany	0.23%
China	0.14%
Ireland	0.11%
Luxembourg	0.07%
Austria	0.05%
Italy	0.03%
Japan	0.02%
Hong Kong	0.02%
Finland	0.02%
Spain	0.01%
South Korea	0.01%

Based on 1000 largest holdings

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.

Employees

711

Sector

Biotechnology & Medical Research

More about the company